Editorial: Modulation of immune function: drug discovery and translational application DOI Creative Commons
Ruirong Tan, Junning Zhao

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 16, 2024

inflammation and reducing disease severity (Yin et al., 2021). Lang al.present an example of traditional medicine's therapeutic potential in immune modulation, focusing on Wuwei Shexiang Pill (WSP). Their research demonstrates that WSP not only ameliorates ankle swelling inflammatory cell infiltration, but also modulates multiple pathways involved inflammation. By employing LC-MS-based metabolomics approach, the study identifies key metabolic influences, offering a comprehensive view how systemic modulation can alleviate diseases. This supports idea medicines, when rigorously tested characterized, be valuable sources for drug discovery immune-related conditions.The responses is crucial addressing diseases such as stroke (Macrez In conclusion, articles this Research Topic offer diverse innovative exploration modulating function lead to novel strategies across range From integration medicines with modern pharmacology use artificial intelligence screening, contributions emphasize importance multidisciplinary approach discovery. These studies provide roadmap future into multiomics techniques, AI-driven methodologies, refinement immunotherapy tackle some most challenging our time. As field continues expand, it evident both approaches will play roles shaping pharmacological interventions. The exemplify ongoing efforts bridge gap between basic immunology translational medicine, driving forward development more precise, effective therapies

Language: Английский

Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges DOI
A. Raja,

Abhishek Kasana,

Vaishali Verma

et al.

Molecular Biotechnology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 2, 2024

Language: Английский

Citations

5
Trends in the research and development of peptide drug conjugates: artificial intelligence aided design DOI Creative Commons

Donge Zhang,

Tong He, Tianyi Shi

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

Peptide-drug conjugates (PDCs) represent an emerging class of targeted therapeutic agents that consist small molecular drugs coupled to multifunctional peptides through cleavable or non-cleavable linkers. The principal advantage PDCs lies in their capacity deliver diseased tissues at increased local concentrations, thereby reducing toxicity and mitigating adverse effects by limiting damage non-diseased tissues. Despite the increasing number being developed for various diseases, advancements remain relatively slow due several development constraints, which include limited available linkers, narrow applications, incomplete evaluation information platforms PDCs. Marked recent Nobel Prize awarded artificial intelligence (AI) de novo protein design "protein structure prediction," AI is playing increasingly important role drug discovery development. In this review, we summarize developments limitations PDCs, highlights potential revolutionizing PDC.

Language: Английский

Citations

0
Utilizing aptamers in targeted protein degradation strategies for disease therapy DOI

Li Lin,

Songbo Xie,

Jun Zhou

et al.

The Journal of Pathology, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy, offering the potential to reduce disease‐causing proteins that have traditionally been challenging target using conventional small molecules. Despite significant advances made with TPD technologies, challenges such high molecular weight, difficulties in identifying suitable ligands, suboptimal absorption, and metabolic instability remain unresolved. Recently, aptamers – single‐stranded DNA or RNA oligonucleotides known for their specificity affinity targets introduced novel opportunities expand scope of TPD, strategy now referred aptamer‐based TPD. This approach demonstrated considerable promise treating various diseases, cancer ocular disorders. For example, an aptamer‐proteolysis‐targeting chimera (PROTAC) conjugate (APC) improved tumor targeting reduced toxicity breast model, vascular endothelial growth factor‐degrading (VED)‐lysosome‐targeting (LYTAC) molecule effectively inhibited abnormal retinal diseases. These examples highlight practical relevance advancing drug discovery efforts. In this review we provide comprehensive overview latest strategies, including proteolysis‐targeting lysosome‐targeting chimeras, emphasizing applications, benefits, well must be overcome fully harness clinical potential. © 2025 The Pathological Society Great Britain Ireland.

Language: Английский

Citations

0
New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates DOI
Matthias Ocker, Christian Mayr, Petra Huber‐Cantonati

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Biliary tract cancer (BTC) is a human malignancy with poor prognosis. However, significant progress has been made in understanding the molecular mechanisms of carcinogenesis, leading to development targeted therapy strategies recent years. The challenge now develop new therapeutic concepts further increase efficacy BTC treatments coming This review covers emerging and advanced approaches highly sophisticated antibody-drug conjugates (ADCs) non-ADCs, particularly relation BTC. Additionally, potential advantages disadvantages ADCs non-ADCs regarding toxicities, bioavailability, are presented discussed. Given prognosis BTCs, precision using drug - without antibodies as carriers have overcome limitations conventional chemotherapy by improving treatment specificity while reducing systemic toxicity. several open questions remain including chemical design, delivery, related diagnostic biomarkers, combinatory application strategies.

Language: Английский

Citations

0
Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)? DOI Creative Commons
Dongyuan Wang, Feng Yin, Zigang Li

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 22, 2025

Drug conjugates have emerged as a promising alternative delivery system designed to deliver an ultra-toxic payload directly the target cancer cells, maximizing therapeutic efficacy while minimizing toxicity. Among these, antibody-drug (ADCs) garnered significant attention from both academia and industry due their great potential for therapy. However, peptide-drug (PDCs) offer several advantages over ADCs, including more accessible industrial synthesis, versatile functionalization, high tissue penetration, rapid clearance with low immunotoxicity. These factors position PDCs up-and-coming drug candidates future Despite potential, face challenges such poor pharmacokinetic properties bioactivity, which hinder clinical development. How design meet needs is big challenge urgent resolve. In this review, we first carefully analyzed general consideration of successful PDC learning ADCs. Then, summarised basic functions each component construct, comprising peptides, linkers payloads. The peptides in were categorized into three types: tumor targeting cell penetrating peptide self-assembling peptide. We then these delivery, overcoming resistance, controlling release improving reduced non-specific To better understand druggability PDCs, discussed pharmacokinetics also briefly introduced current trials. Lastly, perspectives development oncology PDC. This review aimed provide useful information construction applications.

Language: Английский

Citations

0
Recent Advances in Augmenting the Therapeutic Efficacy of Peptide–Drug Conjugates DOI Creative Commons
Jiahui Ma, Xuedan Wang, Yong-hua Hu

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

There is an urgent need for the development of safe and effective modalities treatment diseases owing to drug resistance, undesired side effects, poor clinical outcomes. Combining cell-targeting efficient cell-killing properties, peptide-drug conjugates (PDCs) have demonstrated superior efficacy compared with peptides payloads alone. However, innovative molecular designs PDCs are essential further improving targeting precision, protease resistance stability, cell permeability, overall efficacy. Several strategies been developed address these challenges, such as multivalency approaches, bispecific targeting, long-acting PDCs. Other novel strategies, including overcoming biological barriers, conjugating functional payloads, macropinocytosis, also shown promise. This perspective compiles most recent enhancing PDC efficacy, highlights key advancements in PDC, provides insights on future directions

Language: Английский

Citations

0
Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress DOI Creative Commons
Krishna Jadhav, Ashwin Abhang, Eknath Kole

et al.

Bioengineering, Journal Year: 2025, Volume and Issue: 12(5), P. 481 - 481

Published: April 30, 2025

Peptide–drug conjugates (PDCs) have emerged as a next-generation therapeutic platform, combining the target specificity of peptides with pharmacological potency small-molecule drugs. As an evolution beyond antibody–drug (ADCs), PDCs offer distinct advantages, including enhanced cellular permeability, improved drug selectivity, and versatile design flexibility. This review provides comprehensive analysis fundamental components PDCs, homing peptide selection, linker engineering, payload optimization, alongside strategies to address their inherent challenges, such stability, bioactivity, clinical translation barriers. Therapeutic applications span oncology, infectious diseases, metabolic disorders, emerging areas like COVID-19, several advancing in trials achieving regulatory milestones. Innovations, bicyclic peptides, supramolecular architectures, novel technologies, are explored promising avenues enhance PDC design. Additionally, this examines trajectory emphasizing potential highlighting ongoing that exemplify efficacy. By addressing limitations leveraging advancements, hold immense promise targeted therapeutics capable complex disease states driving progress precision medicine.

Language: Английский

Citations

0
Recent Progress in the Development of Peptide-Drug Conjugates (PDCs) for Cancer Therapy DOI

Haiqi He,

Xin Deng, Zhijie Wang

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 284, P. 117204 - 117204

Published: Dec. 24, 2024

Language: Английский

Citations

1
A Conjugate of an EGFR-Binding Peptide and Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells DOI

Phi-Phung Than,

Shih-Jing Yao,

Emad Althagafi

et al.

ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 16(1), P. 109 - 115

Published: Dec. 12, 2024

Selective targeting of cancer cells via overexpressed cell-surface receptors is a promising strategy to enhance chemotherapy efficacy and minimize off-target side effects. In this study, we designed peptide 31 (YHWYGYTPERVI) target the epidermal growth factor receptor (EGFR) in triple-negative breast (TNBC) cells. Peptide internalized by TNBC through EGFR-mediated endocytosis shares sequence structural similarities with human EGF (hEGF), natural EGFR ligand. Unlike hEGF, does not induce cell migration A novel conjugate doxorubicin (Dox) retains selectivity for exhibits significant toxicity comparable that unconjugated Dox. Importantly, shows no toward normal epithelial up high concentration (25 μM). Thus, serves as versatile ligand developing conjugates EGFR-positive cancers.

Language: Английский

Citations

0
Design, synthesis and activity evaluation of reduction-responsive anticancer peptide temporin-1CEa drug conjugates DOI

Zhenbin Han,

Yue Wang, Wenxuan Wang

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 154, P. 108103 - 108103

Published: Dec. 27, 2024

Language: Английский

Citations

0